National Cancer Institute (NCI) clinical trial failures

Review 374 stopped clinical trials from National Cancer Institute (NCI), including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 19 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials374

Likely biological signals19

Shown below100

Dominant stop reasons

OTHER/UNKNOWN: 181
OPERATIONAL: 173
EFFICACY/FUTILITY: 10
SAFETY: 9
REGULATORY: 1

Notable sponsors

National Cancer Institute (NCI): 374

Related phases

Phase II: 185
Phase I: 169
Phase III: 14
Early Phase I: 6

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT03604991: Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Phase II Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

End of Initial Phase of Multi-phase protocol

NCT04929041: Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase II Lung Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

End of Initial Phase of Multi-phase protocol

NCT05642195: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase I Non-Small Cell Lung Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Revisions to eligibility/design being made prior to enrollment of first participants.

NCT06568172: Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase III Eyelid Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Other

NCT06876142: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Phase I Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Administrative hold pending non-safety related changes to the study design.

NCT03952598: Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

Phase II Glioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Study on hold pending possible updates with the team.

NCT04751383: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Phase I High Risk Neuroblastoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug supply issues

NCT03436745: The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Phase I Prostatic Neoplasms trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Slow/insufficient accrual

NCT05673200: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase I Anatomic Stage III Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - DLT assessment and phase 2 dose determination

NCT04071236: Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase I Metastatic Castration-Resistant Prostate Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - To assess the study's feasibility.

NCT05256225: Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase III Endometrial Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Revisions to ICF

NCT01012297: Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Phase III Recurrent Uterine Corpus Sarcoma trial by National Cancer Institute (NCI). Stop reason: EFFICACY/FUTILITY.

The study was targeted to accrue 130 patients, but closed early for futility.

NCT05554380: Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Phase II Locally Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - study has reached accrual goal for analysis

NCT00520975: Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase III Breast Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Closed early due to slow accrual

NCT04616560: Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Phase I Desmoplastic Small Round Cell Tumor trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - Stage 1 has met accrual

NCT05372614: Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase I Metastatic Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Correlative sample analysis.

NCT05111561: Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase I Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Amendment needed to add new dose level.

NCT07042295: Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Phase II Locally Recurrent Skin Squamous Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - safety run-in for initial cohort of participants

NCT06102902: Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Phase I Metastatic Colorectal Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Pending amendment.

NCT06557733: An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Phase II Colorectal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

New information received

NCT05904080: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Phase II Metastatic Nasopharyngeal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Scheduled Interim Monitoring

NCT06179888: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Phase II Multiple Myeloma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Scheduled Interim Monitoring

NCT04500548: Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Phase I Constitutional Mismatch Repair Deficiency Syndrome trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT05960773: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Phase II Mesothelioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

On hold pending updates to the drug/manufacturer information.

NCT06325683: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase II Progressive Glioblastoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Scheduled Interim Monitoring

NCT03199885: Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase III Metastatic Breast Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT06661915: A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Phase II Accelerated Phase Myeloproliferative Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Protocol amendment to add additional dose levels

NCT03745326: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase I Gastrointestinal Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study was closed due to lack of accrual and study outcomes overlapped with another protocol's eligibility.

NCT03816319: TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Phase I Myelodysplastic Syndrome With Excess Blasts trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Pending amendment addressing dose escalation plan.

NCT05685602: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase I Metastatic Pancreatic Ductal Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug Supply Issues

NCT05223036: Testing Obeticholic Acid for Familial Adenomatous Polyposis

Phase II Attenuated Familial Adenomatous Polyposis trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Protocol has been completed prematurely due to poor accrual and study feasibility.

NCT06802523: Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase I Acute Myeloid Leukemia trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug Supply Issues

NCT04539366: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Phase I Recurrent Childhood Neuroblastoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - review of safety data

NCT06514261: Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

Phase I Acute Myeloid Leukemia trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Pending amendment for study expansion.

NCT04301076: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase I Acute Adult T-Cell Leukemia/Lymphoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Pending amendment.

NCT04840589: Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase I Metastatic Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Pending amendment.

NCT07388563: Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Phase I Lymphoma, T Cell, Peripheral trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

New recruitment on hold for a protocol design amendment/modification.

NCT04034251: Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase II Gastric Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.

NCT07328490: Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase I Extensive-Stage Small Cell Lung Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study drug supplier withdrew support; no participants were enrolled.

NCT03737994: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase II Lung Non-Squamous Non-Small Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT06654050: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase II Mesothelioma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

The study is being withdrawn due to the CRADA with the company not being finalized

NCT04890093: Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Phase I Sarcoma, Ewing trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Pending updated agreements in order to enroll additional participants.

NCT05286827: Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Phase II Pancreatic Acinar Cell Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

The study was terminated due to low accrual and insufficient efficacy seen in first few participants treated.

NCT04166383: VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Phase II Metastatic Colorectal Cancer trial by National Cancer Institute (NCI). Stop reason: EFFICACY/FUTILITY.

Interim analysis indicated limited efficacy

NCT05554354: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase II Anatomic Stage IV Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - slow accrual

NCT03772925: Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase I Recurrent Acute Myeloid Leukemia trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug supply issues

NCT03785210: Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Phase II Hepatocellular Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study was terminated due to poor accrual.

NCT02942264: Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase I Brain Tumor trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Unable to supply investigational agent, Zotiraciclib (TG02).

NCT06603818: Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase II Microsatellite Stable Metastatic Colorectal Cancer trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

The trial is closing due to findings from a related study, prompting the sponsor to discontinue development and end this study.

NCT03165721: A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Phase II Paraganglioma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study closed to enrollment due to low accrual.

NCT03031730: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase I Plasmacytoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT02381548: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Phase I Acute Myeloid Leukemia trial by National Cancer Institute (NCI). Stop reason: SAFETY.

Other - Adverse Events

NCT00923806: Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer

Phase I Metastatic Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study was terminated due to poor accrual.

NCT06865677: Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase II Recurrent Platinum Resistant Epithelial Ovarian Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.

NCT02408861: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase I Advanced Malignant Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT02948426: Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Phase I Fallopian Tube Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study was closed to accrual due to lack of drug supply.

NCT05035407: T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase I Kita-kyushu Lung Cancer Antigen 1, Human trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Site plans to become a site for a multicenter study of this therapy

NCT05918055: Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Phase I Myelodysplastic Syndromes trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug company withdrew support.

NCT03107780: Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Phase I Glioblastoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug supply issues

NCT05564416: Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Phase II Bladder Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Feasibility issues

NCT04541017: Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase I Mycosis Fungoides trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug supply issues

NCT06730100: CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase II Metastatic Mismatch Repair Proficient Colorectal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

no accruals

NCT04458909: Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase III Metastatic Nasopharyngeal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

External information

NCT05198843: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Phase I Anatomic Stage IV Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - Poor accrual

NCT04108858: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Phase I Anatomic Stage IV Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT05148234: BMS-986253 in Myelodysplastic Syndromes

Phase I Myelodysplastic Syndromes trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Company closed the trial.

NCT04372641: Testing the Safety of CB-5339 in Patients With Cancer

Phase I Aggressive Non-Hodgkin Lymphoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Clinical development of the agent has been discontinued

NCT06410534: A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase II Colorectal Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

PI left NIH.

NCT06690281: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase II Gastrointestinal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

PI left NIH.

NCT05009979: 18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Phase II Hepatocellular Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Reason for termination was a combination of slow accrual in setting of austerity measures regarding resource allocation.

NCT04936230: Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Phase II Metastatic Urothelial Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT03018288: Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Phase II Glioblastoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study closed early due to poor accrual.

NCT06161558: Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase I Neoplasms trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Lack of resources to complete study objectives. No participants enrolled.

NCT05879484: Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Phase I Sinonasal Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study was never opened for enrollment as the CRADA was never executed

NCT06590558: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase I Anatomic Stage III Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Manually added per CS0177524- Weekly CTEP status report.

NCT03724084: Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

Phase I Acute Myeloid Leukemia trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Study agent no longer available

NCT06393751: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Phase I Platinum-Refractory Fallopian Tube Carcinoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Protocol moved to Withdrawn

NCT04406857: Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

Phase I Locally Advanced Rectal Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT04370834: Tocilizumab for Patients With Cancer and COVID-19 Disease

Phase II Hematopoietic and Lymphoid Cell Neoplasm trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Randomized data no longer support continuation

NCT04538378: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase II EGFR-Mutated Non-Small-Cell Lung Carcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Closed due to slow accrual.

NCT06328036: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase II Recurrent Glioblastoma, IDH-Wildtype trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Protocol moved to Disapproved

NCT00798265: A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Phase I Human Immunodeficiency Virus trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study closed due to low accrual.

NCT01217411: RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Phase I Adult Solid Neoplasm trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - Protocol moved to Administratively Complete

NCT01413750: Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase II Stage IIIA Lung Non-Small Cell Cancer AJCC v7 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

CTEP Initiated Action

NCT02097225: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase I BRAF V600E Mutation Present trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Drug supply issues

NCT05898828: Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Phase I Neoplasms trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

No enrollment

NCT04933617: Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase I Burkitt Lymphoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.

NCT02876640: Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

Phase I Anatomic Stage I Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate Accrual Rate

NCT03300544: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Phase I Locally Advanced Rectal Adenocarcinoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Inadequate accrual rate

NCT05411107: Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Phase II Bronchial Epithelial Dysplasia trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Agent is not available

NCT06210750: Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Phase II T Acute Lymphoblastic Leukemia trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Protocol moved to Disapproved

NCT06400264: Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

Phase II Advanced Lymphoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

No result will be reported- no patient accrued. Status Withdrawn: Study halted prematurely, prior to enrollment of first participant."

NCT05807126: Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase I Anatomic Stage IV Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

No subjects enrolled in the study

NCT04027946: LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase II Lung Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Study was terminated due to slow accrual.

NCT02133183: Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Phase I Glioblastoma trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Other - Lapse in funding

NCT05445882: N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Phase II Castration Resistant Prostate Cancer trial by National Cancer Institute (NCI). Stop reason: OPERATIONAL.

Closed by study team, no subjects enrolled.

NCT05711628: A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Phase III Recurrent Classic Hodgkin Lymphoma trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Protocol moved to Withdrawn

NCT05967286: Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Phase II Anatomic Stage III Breast Cancer AJCC v8 trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Other - Protocol moved to Withdrawn

NCT04102436: Non-Viral TCR Gene Therapy

Phase II Endocrine/Neuroendocrine trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

Difficulty with availability of GLP-grade reagents for manufacturing.

NCT00019695: Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Phase II Stage IV Prostate Cancer trial by National Cancer Institute (NCI). Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.